Alvotech and JAMP Pharma have entered into an exclusive partnership to commercialize five key biosimilars in the Canadian market. According to Alvotech, the current market value of the branded sales for these biosimilars is estimated to exceed $2bn annually.
Privately-owned JAMP Pharma will have exclusive rights to commercialize Alvotech’s biosimilars in Canada, while Alvotech will be responsible for full development and commercial supply of the